Vertex Pharmaceuticals
From Wikipedia, the free encyclopedia
 |
The neutrality of this article is disputed. Please see the discussion on the talk page. Please do not remove this message until the dispute is resolved. |
| Vertex Pharmaceuticals Incorporated | |
|---|---|
| Type | Corporation (NASD: VRTX) |
| Founded | 1989 |
| Headquarters | Cambridge, Massachusetts |
| Key people | Joshua Boger, Ph.D., President, Chairman, CEO; |
| Products | Product Pipeline |
| Revenue | ▲ $250 million USD (2006) |
| Website | www.vrtx.com |
Vertex Pharmaceuticals is a biotechnology company with activities spanning the length of the pharmaceutical product pipeline, from target identification through to clinical trials and marketing. Most of their activity has been in collaboration with much larger pharmaceutical firms, though some of their recent work has been done independently. Vertex was founded in 1989 by Josh Boger; one of the main reasons for Vertex's success. He was an outstanding fund raiser and able to manage the company's cash flow very well. Vertex was one of the first bio-tech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. Vertex went about understanding a disease and then tried to develop a process to cure it. In 2004, their product pipeline focused on viral infections, inflammatory and autoimmune disorders and cancer. Their capital investments include a headquarters facility in Cambridge, Massachusetts and two research facilities, in San Diego, California and Oxford, United Kingdom. The company was profiled by Barry Werth in the book Billion Dollar Molecule.
[edit] References
- Vertex Pharmaceuticals Incorporated homesite. 2004 Annual Report. Retrieved on 18 May 2004.
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
